| ABT-263 (navitoclax) |
ENSG00000005206.12 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000088970.11 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000149656.4 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000157306.10 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000157306.10 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000157306.10 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000164621.5 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000166770.6 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000168367.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000170846.11 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000170846.11 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000172965.10 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000173867.8 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000174365.15 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000175699.8 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000175773.8 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000175967.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000177337.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000177757.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000177853.10 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000179818.9 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000179935.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000179935.5 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000180712.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000181097.5 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000182586.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000182586.3 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000184274.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000185168.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000185203.7 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000185203.7 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000186594.8 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000187904.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000188206.5 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000188660.3 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000188660.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000189149.7 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000189238.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000196421.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000196566.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000196756.7 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000196756.7 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000196960.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000196972.6 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000197291.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000197308.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000197308.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000197332.7 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000198221.7 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000203325.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000203325.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000203362.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000203441.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000203593.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000203650.3 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000203709.5 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000203739.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000203739.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000203808.6 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000203809.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000204011.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000204011.4 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000204054.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000204362.5 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000204685.5 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000204837.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000204929.7 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000205041.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000205041.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000205500.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000205500.4 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000205500.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000205837.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000205885.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000205959.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000206573.4 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000213742.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000213963.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000213971.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000214347.5 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000214353.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000214353.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000214407.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000214407.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000214407.3 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000214432.5 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000214773.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000214894.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000214922.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000215039.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000215068.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000215190.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000215241.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000215424.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000215447.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000215808.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000215863.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000215863.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000215863.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000215866.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000219665.4 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000219665.4 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000220161.4 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000222032.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000222043.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223380.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000223390.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223393.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223393.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000223396.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223401.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223404.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223414.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223461.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223462.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000223473.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000223475.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223477.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223477.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000223511.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223522.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223542.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223561.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223571.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223586.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223608.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223669.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223695.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223697.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000223701.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223704.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000223711.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223745.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000223759.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223759.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223768.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000223768.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223774.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223779.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223804.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223804.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000223812.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223855.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000223891.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223935.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223960.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000223966.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000224029.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000224032.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224032.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000224034.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224043.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224043.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000224077.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224078.8 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224078.8 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224093.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224138.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224138.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000224222.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224251.2 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000224251.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224269.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224276.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224276.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224409.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224413.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224429.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224460.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224460.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224468.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224481.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224490.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224616.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224621.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000224635.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224660.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224713.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224713.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224761.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224805.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224817.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224822.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224846.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224855.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224885.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224888.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224888.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224939.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224945.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224950.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224959.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000224969.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224975.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000224985.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000225032.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225037.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000225039.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225039.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225075.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000225096.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000225112.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225163.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225218.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225218.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000225234.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225234.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000225439.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000225506.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225506.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225518.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000225527.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000225541.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000225555.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225555.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000225572.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225643.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000225684.3 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000225760.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225778.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000225778.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225778.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225793.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000225806.3 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000225857.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225914.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000225914.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000225930.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000225975.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000225981.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000225981.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000226007.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226007.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226007.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000226026.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000226067.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226067.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000226091.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000226179.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226200.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000226207.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226287.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226287.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226310.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226312.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226328.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000226352.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226377.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226380.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000226390.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226445.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000226465.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226519.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226520.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000226533.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000226581.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000226637.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000226637.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000226659.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226696.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226699.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000226740.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226756.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226816.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000226824.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000226904.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000226920.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000226920.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000226950.2 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000227006.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227014.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227014.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227028.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227045.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000227071.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227076.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227083.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000227116.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227117.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227155.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227170.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227188.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227200.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227218.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227240.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227248.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227256.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227258.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000227279.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227285.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227285.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227354.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227355.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227372.6 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227372.6 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000227374.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227431.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000227477.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227487.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227487.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227496.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227533.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227533.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227543.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227543.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227591.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227598.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227637.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227674.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227704.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227706.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227711.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227733.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000227741.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227769.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227932.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227945.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227954.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000227959.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000227959.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000228013.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000228022.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000228022.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000228028.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000228060.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000228079.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228115.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228140.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228150.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000228150.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228150.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000228151.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228237.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000228251.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228265.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228274.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228302.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228389.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228404.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228412.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228412.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228506.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228509.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228544.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000228548.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000228577.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000228614.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000228614.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228629.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000228649.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228661.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228680.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228686.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228692.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228705.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228723.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000228798.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000228817.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228839.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228857.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000228889.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000228906.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000228939.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000228939.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000229036.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000229056.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229105.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229311.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229325.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229431.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000229487.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229491.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000229512.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000229512.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229582.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229587.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000229589.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229621.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000229688.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229702.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229702.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000229801.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000229832.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229847.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000229867.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229867.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000229891.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229891.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000229915.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000229950.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000229951.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000229967.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000229980.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000229999.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230021.3 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000230061.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230068.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000230074.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230082.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230105.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230107.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230155.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230176.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230212.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000230266.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000230300.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000230337.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230366.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230424.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000230433.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230470.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000230487.3 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000230499.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000230530.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000230530.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000230534.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000230587.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230615.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230648.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230730.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230731.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230732.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230736.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000230753.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230806.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230806.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230826.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000230826.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230850.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230910.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230912.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000230943.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231010.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231023.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000231028.4 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231028.4 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231073.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000231081.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231149.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231154.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231185.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231187.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000231196.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231201.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231201.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231249.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231290.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000231294.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231310.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231327.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231327.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231346.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231407.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000231439.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000231481.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000231512.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231521.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000231551.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231563.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231611.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231646.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231646.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231652.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000231663.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000231663.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000231691.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231728.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000231734.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000231742.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231760.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231811.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000231840.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000231851.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231858.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000231858.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231865.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231920.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231944.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000231992.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000231993.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000231993.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232034.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232043.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232082.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232086.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000232093.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232098.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000232117.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232124.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000232139.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232160.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232160.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000232160.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000232194.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232194.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232224.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232274.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232290.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232300.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232324.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232336.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232377.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232412.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232415.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232490.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232504.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000232533.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232593.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232600.2 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000232600.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232618.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232640.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232645.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232656.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232677.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232677.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000232686.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232692.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232693.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232719.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232725.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232732.5 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232732.5 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000232754.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232762.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232788.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232788.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000232828.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232855.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232876.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232907.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232909.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000232913.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000232931.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232935.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232936.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232940.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232940.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000232940.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000232973.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233017.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233030.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233030.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233033.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233056.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233058.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233058.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000233069.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000233081.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233203.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000233223.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233293.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233330.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000233360.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233368.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233411.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233429.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233430.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233461.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233491.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233547.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233559.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233621.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233661.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233695.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000233757.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233757.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233766.3 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000233775.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000233783.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233799.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000233817.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233818.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233844.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000233845.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000233847.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233847.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233862.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000233906.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234006.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234147.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234155.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234155.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234160.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234199.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234232.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234233.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234264.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234286.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234290.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234292.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234350.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000234362.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234393.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234394.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234396.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234405.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000234456.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000234459.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234459.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234478.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234535.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234556.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234567.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234567.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000234617.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000234630.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234665.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000234689.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234694.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234694.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234698.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234705.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234740.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234740.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000234741.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000234771.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234771.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234772.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234817.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234817.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234848.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234859.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234880.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000234899.5 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000234902.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234915.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000234915.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000234915.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000234943.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000234996.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000234997.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235027.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235052.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235079.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000235091.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235092.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000235117.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000235117.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000235119.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235185.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000235204.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235244.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235245.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235269.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235285.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235296.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000235358.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235358.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235373.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000235381.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235381.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235398.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235398.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235398.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000235408.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235419.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235426.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235427.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235445.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235477.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000235481.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235499.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235499.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235527.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235560.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235565.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235664.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000235760.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235760.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235770.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235772.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235790.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235806.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235806.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000235837.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235848.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235852.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235872.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235908.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235919.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235927.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235927.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000235954.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000235999.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000235999.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000236024.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236065.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000236115.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000236209.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236212.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236256.5 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000236262.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236305.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236337.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236345.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236383.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000236385.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000236390.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000236427.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000236526.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236528.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236535.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000236540.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236581.4 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236591.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000236651.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000236711.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000236751.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236772.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236780.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000236833.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000236861.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000236869.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236869.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000236869.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000236896.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000236901.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000236936.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000236943.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000236943.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000236943.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000236986.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237036.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237126.4 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000237133.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000237152.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237159.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237167.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237181.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237187.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237234.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237248.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237253.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237281.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000237291.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237298.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000237324.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237343.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000237371.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237399.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237402.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000237424.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237438.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000237453.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237471.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237476.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237499.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237512.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237517.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237523.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237594.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237594.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237595.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237605.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000237689.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237718.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237738.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237753.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237756.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000237781.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000237803.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237807.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237807.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237813.3 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237862.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237892.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237943.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237976.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000237978.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000237989.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000238005.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000238035.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000238043.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000238062.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000238113.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000238120.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000238160.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000238186.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000238197.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000238287.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000239300.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000239353.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000239480.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000239569.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000239653.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000240057.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000240057.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000240063.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000240086.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000240137.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000240211.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000240288.3 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000240350.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000240401.4 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000240453.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000240453.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000240476.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000240497.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000240541.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000240790.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000240875.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000240907.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000240990.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000240990.5 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000240996.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000241014.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000241054.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000241155.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000241155.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000241280.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000241280.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000241313.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000241313.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000241316.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000241479.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000241599.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000241770.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000241954.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000241985.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000241985.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000242082.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000242086.4 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000242125.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000242391.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000242474.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000242516.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000242516.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000242516.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000242553.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000242569.3 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000242686.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000242687.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000242767.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000243069.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000243243.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000243243.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000243350.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000243368.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000243797.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000243967.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244063.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000244124.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244128.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244161.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000244198.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244203.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000244268.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244302.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244327.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244327.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000244332.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244459.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000244479.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244578.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000244586.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000244733.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244945.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244945.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000244968.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000245060.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000245067.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000245293.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000245498.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000245532.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000245571.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000245573.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000245598.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000245648.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000245685.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000245748.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000245748.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000245748.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000245768.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000245904.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000245910.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000245928.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000245975.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000246090.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246090.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246225.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246250.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246250.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246331.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000246334.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246379.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246422.2 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000246465.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000246523.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246528.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246528.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000246627.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246790.2 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000246792.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000246859.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246859.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246876.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000246898.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000246898.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247134.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247137.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247317.3 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247373.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000247373.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000247400.3 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247416.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247516.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000247516.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247516.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000247556.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000247572.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000247679.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247708.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000247708.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000247774.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000247774.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247828.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247877.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000247970.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000248100.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000248202.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000248223.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000248223.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000248318.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000248323.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000248356.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000248388.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000248461.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000248508.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000248515.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000248677.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000248693.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000248724.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000248774.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000248774.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000248787.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000248810.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000248844.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249035.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000249084.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249131.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000249159.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000249241.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000249249.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000249252.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249307.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249328.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249345.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249348.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000249352.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249359.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249430.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249487.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249494.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000249532.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249572.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249602.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000249602.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000249602.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249614.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249637.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000249650.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000249685.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249695.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249706.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249713.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249738.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000249740.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000249753.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000249803.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000249859.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249898.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000249984.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000249996.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250007.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250061.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250131.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250133.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250155.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000250156.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000250258.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250303.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000250326.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000250362.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250366.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250548.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000250635.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000250657.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000250659.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000250659.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250699.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250764.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250764.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250802.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000250820.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000250874.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250874.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000250910.3 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000250938.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000250948.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000250988.3 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000250994.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251003.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000251003.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251009.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251022.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251026.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251085.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000251095.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000251131.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000251141.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251141.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000251143.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251151.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000251179.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000251194.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000251216.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251298.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000251309.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251314.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000251323.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251359.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251387.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000251396.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000251409.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000251432.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251442.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000251455.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251555.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000251556.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251562.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251574.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251598.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251603.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000251611.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251615.3 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251652.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000251666.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253106.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253112.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253125.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253187.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253210.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253210.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253227.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253327.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253327.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253335.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253374.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253390.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000253395.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253414.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253476.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253477.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253508.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253535.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253559.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000253562.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000253576.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253616.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253618.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253632.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253695.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000253708.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253712.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253736.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253741.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000253744.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253744.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000253744.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253837.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253848.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000253875.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253893.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000253917.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000253978.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000253978.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254028.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254057.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000254057.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000254164.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254165.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254204.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254204.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000254248.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254267.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000254286.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254286.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254314.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254340.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254341.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254353.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000254363.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000254363.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254370.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000254397.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254397.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000254409.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254419.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000254428.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254431.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000254433.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000254459.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000254484.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254484.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000254485.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254489.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000254495.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000254495.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000254510.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254510.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254538.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000254560.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254560.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000254606.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254615.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000254639.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000254662.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000254664.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254670.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254687.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254691.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000254694.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254703.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000254762.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254791.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254821.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000254847.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000254973.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000255008.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000255020.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255026.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000255027.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000255027.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255045.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255052.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000255164.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000255182.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000255197.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000255321.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255322.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255322.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000255325.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255343.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255343.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255348.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255355.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000255364.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000255414.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255443.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000255455.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000255474.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255509.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000255521.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255557.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000255557.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000255571.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000255571.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255571.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255621.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000255651.2 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000255651.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000255843.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255847.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000255857.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000255857.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255857.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000255864.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000255867.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000255946.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255970.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000255992.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000255992.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256006.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000256050.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000256083.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000256128.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000256128.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256268.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256321.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256433.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256448.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256458.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256458.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000256546.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256546.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000256596.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256603.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256603.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000256705.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256712.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000256742.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256742.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000256746.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000256894.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000256967.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000256982.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257086.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257135.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257151.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000257151.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000257219.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000257221.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000257222.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257252.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257261.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257261.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257272.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000257272.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257337.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257337.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257337.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000257337.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257337.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257354.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257391.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257410.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000257410.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000257433.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000257433.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257443.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257443.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257449.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257467.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257475.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257496.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257497.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000257497.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257556.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257596.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257636.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257642.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000257647.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000257660.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000257696.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257702.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257718.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257732.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000257735.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000257740.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257809.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257829.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257894.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257910.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257913.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000257925.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000257964.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258034.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258048.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258057.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258082.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000258086.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258096.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258096.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258122.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258136.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258199.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000258260.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258303.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258334.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258334.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258344.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258410.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258413.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258413.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000258441.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258450.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258450.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258515.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000258520.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258553.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258553.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000258556.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258602.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258620.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258646.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258667.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258689.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000258711.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258725.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000258725.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258733.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258777.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258789.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258808.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258821.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258825.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258825.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258920.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258926.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258929.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000258935.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258959.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000258982.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000258998.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259038.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259062.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259073.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259083.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000259088.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259125.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259126.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259135.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000259146.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259206.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000259206.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259219.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259238.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000259241.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259274.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259274.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000259294.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259296.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259310.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000259310.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259319.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000259341.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259343.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000259364.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259366.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259398.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259408.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259415.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000259416.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259416.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000259416.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259417.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259442.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259456.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259462.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259514.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000259515.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259523.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259523.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259540.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259548.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259583.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259590.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000259606.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259623.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259644.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000259650.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259656.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000259668.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259687.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259712.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259758.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000259782.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259792.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259805.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000259807.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259826.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259828.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259834.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259863.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259863.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000259867.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259876.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000259886.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259921.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000259926.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000259933.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000259943.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000259959.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000259974.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260017.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000260017.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260021.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260034.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260034.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260038.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000260065.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260083.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260091.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000260101.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260156.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260179.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260185.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000260186.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260194.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000260209.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260213.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260248.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260260.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000260276.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000260293.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260306.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260306.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260306.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000260328.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260336.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260336.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000260360.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260361.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260364.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260366.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260368.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260388.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260394.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260400.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260400.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260411.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260411.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000260447.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260448.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000260466.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260469.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260473.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000260509.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260528.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000260534.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000260545.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000260583.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260589.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260597.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260604.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260608.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260614.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260614.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260635.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260637.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000260643.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000260660.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260661.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260693.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260693.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260743.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260743.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000260744.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260751.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260757.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260803.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000260831.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000260833.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260834.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260837.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260837.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000260841.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260871.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260874.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260874.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000260896.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260905.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260905.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000260905.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260910.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260912.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260917.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000260924.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260931.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260932.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260941.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260973.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000260973.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000260988.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261008.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261015.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261039.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261051.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261055.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261064.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261068.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261069.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261095.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000261095.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000261098.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261101.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000261114.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000261117.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261118.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261122.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261124.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261135.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261141.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000261167.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261186.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261187.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000261189.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261254.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261266.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261267.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000261268.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000261270.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261270.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000261286.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261288.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261288.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261291.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000261295.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000261334.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261334.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261338.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000261338.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261369.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261373.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000261428.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000261428.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000261430.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000261431.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261455.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261468.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000261471.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261485.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261490.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261490.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261512.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261512.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000261512.2 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000261513.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261519.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261526.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000261533.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261537.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261578.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000261595.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261595.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000261596.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261600.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261613.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261616.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261618.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261632.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000261634.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261644.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261644.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000261646.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000261670.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261690.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261744.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261751.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261757.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261761.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261766.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261766.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000261775.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261780.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000261799.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261801.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000261864.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000261916.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261971.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000261978.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262001.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262089.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262115.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000262136.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000262136.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262147.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262147.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262155.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262172.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262188.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000262202.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262202.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262202.3 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000262222.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000262292.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262313.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000262319.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262412.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000262412.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000262434.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262454.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262468.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262514.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262585.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000262652.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262662.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262686.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262692.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262703.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262766.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262769.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000262833.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262903.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000262905.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000262951.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000262979.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000262979.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263050.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263063.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000263069.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263080.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263105.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000263105.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000263120.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263176.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000263272.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263327.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263393.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263393.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263400.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263466.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263466.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000263603.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000263731.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263859.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263860.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263906.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000263923.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000263938.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000264083.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000264270.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000264304.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000264339.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000264448.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000264456.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000264469.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000264595.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000264635.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000264647.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000264769.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000264812.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000264829.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000264860.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000264885.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000264914.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000264940.2 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000265185.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265205.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000265205.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265222.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265242.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000265282.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265399.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265443.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000265445.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000265451.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265479.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265490.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000265554.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265666.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000265688.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265688.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000265688.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265717.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265749.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265766.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000265778.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000265787.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265800.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265912.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000265943.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000265992.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000266053.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000266079.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000266120.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000266236.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266313.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266401.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000266401.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266498.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000266538.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266654.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000266664.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266801.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266801.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000266805.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266805.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266824.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266895.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000266900.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000266903.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000266930.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266933.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266935.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000266936.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266942.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266947.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000266965.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266970.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266978.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000266993.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266999.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000266999.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000267002.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267009.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267016.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267035.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000267040.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267052.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267052.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267096.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267118.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267118.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000267128.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267152.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267201.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267232.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000267244.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267244.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267249.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267254.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267263.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267263.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267268.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267274.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267279.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000267282.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000267296.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000267302.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267375.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267381.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267390.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267414.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267416.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267432.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267446.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267470.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267481.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267481.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267481.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267505.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000267519.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267530.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267530.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267547.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267563.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267578.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267581.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267581.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267583.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267637.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267644.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267649.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267651.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267651.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267658.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267666.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000267677.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267751.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267787.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267798.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000267852.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000267874.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267886.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000267919.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267934.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267934.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000267939.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000267940.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268015.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268049.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000268164.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000268199.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000268199.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268262.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000268366.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268471.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000268520.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268543.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000268549.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000268564.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000268564.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268601.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268605.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268670.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268686.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268746.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000268812.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000268812.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268812.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268912.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000268947.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000268970.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000269019.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269102.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269107.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269148.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269161.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000269172.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269194.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000269202.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269400.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000269400.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269425.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269439.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269480.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000269487.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269489.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269534.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269535.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269560.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269688.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269694.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269736.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269737.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000269737.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269752.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269792.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269814.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269887.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269889.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269893.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000269894.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269899.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269901.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269902.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269924.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269924.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000269924.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000269942.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269961.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269967.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269973.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000269976.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269983.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000269987.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270012.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000270018.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270019.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270031.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270040.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270050.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000270052.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000270062.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270062.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270067.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000270068.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270069.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270074.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000270081.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270084.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270084.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000270084.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270116.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270116.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270117.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000270127.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270141.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270157.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270164.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000270165.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270171.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000270173.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270173.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270174.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270189.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270190.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270210.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270237.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270246.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270346.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270557.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270640.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270640.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270750.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270750.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000270760.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000270760.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270761.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270761.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270761.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000270828.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270949.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000270949.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270964.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000270964.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000270988.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271147.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271151.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271200.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271204.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000271265.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271324.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000271327.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271347.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000271387.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271387.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000271555.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271579.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271590.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000271631.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271646.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000271709.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000271722.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000271738.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271743.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271751.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000271762.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271789.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271803.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271803.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000271803.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271803.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271811.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000271824.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000271825.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271830.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271855.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271856.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000271857.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000271874.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000271888.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271921.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000271948.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271966.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000271975.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000271992.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000271997.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272030.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000272030.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272077.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000272077.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000272079.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272094.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272123.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272142.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272144.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272167.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272181.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000272183.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272211.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272216.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272216.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272216.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272221.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272226.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272235.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272255.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272265.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272274.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000272282.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272308.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272335.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272335.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000272343.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272361.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272365.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000272366.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272368.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272369.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000272373.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272375.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272379.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000272379.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272386.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000272386.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000272416.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272416.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000272432.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000272438.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000272440.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272452.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272452.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272457.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272461.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272473.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272483.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000272512.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272518.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000272555.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000272574.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000272627.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272631.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000272660.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272666.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272668.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272669.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272688.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272702.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272709.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272734.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272744.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000272755.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272755.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272755.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272755.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000272760.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272761.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272764.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272764.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272769.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272769.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272782.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272784.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272787.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272791.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272792.1 |
Predicted lncRNA |
Sarcoma |
|
| ABT-263 (navitoclax) |
ENSG00000272795.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272796.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272796.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272798.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272828.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272829.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272829.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272832.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272836.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272846.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272855.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272858.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000272859.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272859.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000272862.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272862.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272885.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272888.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272912.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272913.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272914.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272931.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000272942.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272945.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000272949.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272950.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272950.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272954.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272954.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000272977.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272989.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000272989.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273001.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273004.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273027.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000273032.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273035.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273058.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000273059.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000273065.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273075.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000273076.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273081.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273096.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000273097.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000273123.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273123.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273129.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273131.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000273133.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273139.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273143.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273148.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273160.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273174.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273183.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273186.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273193.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273203.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000273209.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273216.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273237.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000273243.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273247.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273247.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273248.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273265.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273271.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273289.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| ABT-263 (navitoclax) |
ENSG00000273295.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| ABT-263 (navitoclax) |
ENSG00000273305.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273307.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273308.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273309.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| ABT-263 (navitoclax) |
ENSG00000273319.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273341.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273342.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273350.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273368.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| ABT-263 (navitoclax) |
ENSG00000273428.1 |
Predicted lncRNA |
Esophageal cancer |
|
| ABT-263 (navitoclax) |
ENSG00000273451.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273472.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| ABT-263 (navitoclax) |
ENSG00000273481.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| ABT-263 (navitoclax) |
miR-101 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-105 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-1233 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-148b* |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-153 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-193a |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-218-1* |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-29b-1 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-29b-2* |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-380 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-518a |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-582 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-605 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-661 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-744* |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-876 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-886 |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-892b |
Curated miRNA |
colorectal cancer |
|
| ABT-263 (navitoclax) |
miR-935 |
Curated miRNA |
colorectal cancer |
|
